Check out your Company Bowl for anonymous work chats.
Salt Lake City is our hometown, and we take our community seriously. Thanks to all the friends and family who joined this year’s hashtag#SailFest2024 to support the environmental rejuvenation of the Great Salt Lake and learn how we can contribute to preserving this incredible local resource. Thanks to our partners at Conserve Utah Valley for hosting such a great event! Many thanks to our local teammates who helped create and capture this event!
Honored to be included on the Women Tech Council’s 2024 Shatter List! This recognition is based on our efforts to create progress towards breaking the glass ceiling for women in tech. As of April 2024, 63.1% of Myriad Genetics employees are women.
Thank you to Disability:IN and AAPD Foundation for recognizing us as a top-scorer on the Disability Equality Index! We’re proud of our progress on our #DisabilityInclusion journey, and we look forward to further advancing this work to reach full inclusion and equality.
We recently announced an agreement with The University of Texas MD Anderson Cancer Center to support research focused on metastatic renal cell carcinoma treatment selection and response. The project will use our minimal residual disease (MRD) testing platform, a tumor-informed high-definition assay that detects circulating tumor DNA (ctDNA). “We look forward to supporting this important research collaboration on metastatic renal cell carcinoma with our high-definition MRD research testing platform based on whole-genome sequencing,” said Dale Muzzey, chief scientific officer, Myriad Genetics. “Whereas most currently available MRD tests monitor 50 or fewer variants from the tumor, we suspect our MRD assay will be more sensitive in RCC because it tracks up to thousands of variants identified by sequencing the tumor's whole genome.”
In celebration of #DNADay23, Dale Muzzey, chief scientific officer at Myriad, stopped by the lab to talk about how the power of DNA and genetic insights can shed light on your health. Visit our website to learn more about genetic testing: www.myriad.com
Today, we took an important step to expand access to genetic insights and help address racial and ethnic disparities in healthcare. With the newest version of Myriad’s MyRisk Hereditary Cancer Test, now including RiskScore for all ancestries, all women can receive a personalized polygenic breast cancer risk assessment together with the market’s most accurate hereditary cancer test.
MyRisk Hereditary Cancer Update Article and Video!
Check out our new branding!
Black History Month Newsletter
Myriad receives top workplace in the US from Energage!
